Bariatric surgery produces weight loss partly by increasing appetite-suppressing gut hormones like GLP-1, PYY, and oxyntomodulin while decreasing the hunger hormone ghrelin.
Multiple hormones changeBariatric surgery simultaneously increases at least four satiety hormones and decreases the hunger hormone ghrelin
What the researchers found
Appetite is regulated by two sets of neurons in the hypothalamus. POMC neurons (activated by satiety hormones) suppress appetite. NPY/AgRP neurons (activated by hunger signals) promote eating. Gut hormones modulate this balance.
After bariatric surgery, the key changes include: increased GLP-1 (which suppresses appetite and improves blood sugar), increased PYY (peptide YY, which signals fullness), increased oxyntomodulin (which reduces food intake), and decreased ghrelin (the hunger hormone).
The review highlights that GLP-1 receptor agonists pharmacologically replicate part of this post-surgical response. This explains their effectiveness for weight loss even without surgery. The review also notes that genetic testing can now identify monogenic and polygenic obesity, potentially guiding individualized treatment.
Why it matters
Understanding why bariatric surgery works at the hormonal level has directly led to the development of GLP-1 drugs for weight loss. This review connects the dots between surgical outcomes, gut hormone physiology, and drug development. It also introduces the concept of personalized obesity treatment based on genetic profiles.
The numbers in context
- GLP-1, PYY, oxyntomodulin, CCK: increased after bariatric surgery
- Ghrelin: decreased after bariatric surgery
- POMC neurons: activated by anorexigenic hormones
- NPY/AgRP neurons: activated by orexigenic signals
- Obesity has both monogenic and polygenic genetic components
How the study worked
Narrative review of the physiology of appetite control, including the hypothalamic arcuate nucleus signaling, gut-brain hormone communication, bariatric surgery outcomes, and obesity genetics. Covers both basic science and clinical evidence.
Who was studied
Review of appetite physiology, bariatric surgery outcomes, and obesity genetics
What this study cannot tell us
This is a narrative review without systematic methodology or pooled analysis. It covers a broad scope (physiology, surgery, genetics, pharmacology) at a high level without deep analysis of any single topic. The genetic section is brief and does not detail specific gene-treatment matching. The review does not address long-term safety of GLP-1 drugs or compare them quantitatively to surgery.
How to read the evidence
Rated strong: comprehensive review synthesizing well-established physiological mechanisms with extensive supporting evidence from surgery and pharmacology research.
When this study was published
Published in 2024. Integrates decades of gut hormone research with current understanding of obesity pharmacotherapy.
The bigger picture
Understanding why bariatric surgery works at the hormonal level directly led to GLP-1 weight loss drugs. This review connects surgical outcomes to pharmaceutical development.
Questions still open
- Could a multi-hormone drug cocktail replicate the full effect of bariatric surgery?
- Does ghrelin suppression contribute more to weight loss than GLP-1 elevation?
Common questions
Why does bariatric surgery cause weight loss?
How did bariatric surgery lead to GLP-1 drugs?
Read the original research
Physiological Appetite Regulation and Bariatric Surgery.
Journal of clinical medicine, 13(5)
Citation
Ramasamy, Indra. (2024). Physiological Appetite Regulation and Bariatric Surgery.. Journal of clinical medicine, 13(5). https://doi.org/10.3390/jcm13051347